Dr David Z. Cherney is an associate professor of medicine in the Division of Nephrology at the University of Toronto, Ontario, Canada. He is the director of the Renal Physiology Laboratory, a clinician scientist, and a physician in the Division of Nephrology at Toronto General Hospital.
Dr Cherney’s research interests focus on the relationship between type 1 diabetes and renal haemodynamic function, the renin–angiotensin system, uric acid, urinary biomarkers and glucose-lowering therapies.
He has acted as a consultant for Astellas, Boehringer Ingelheim, Merck, Lilly, AstraZeneca and Janssen. He has also received research funding from Astellas, Boehringer Ingelheim, AstraZeneca and Merck.